Michael G. Raab , BA

Partner
New Enterprise Associates
Menlo Park

Mike joined NEA in June 2002 and specializes in healthcare investments focusing on biotechnology and pharmaceutical sectors. He currently serves on the boards of BioMedicines, CellGate and Novacea. Prior to joining NEA, Mike was most recently Senior Vice President, Therapeutics and General Manager, Renagel at Genzyme Corporation where he turned Renagel into a $1 billion opportunity. Prior to that, Mike was Vice President of Business Development for the Therapeutics Division, responsible for the identification and in-licensing of new therapeutic product opportunities. He gained extensive international experience while building a commercial operation in Latin America for the Therapeutics and Surgical Products groups for the company. Mike was also Product Manager for Ceredase and was instrumental in the worldwide launch of Cerezyme, Genzyme?s $600 million therapies for Gaucher Disease. Mike also spent two years with Genzyme?s Diagnostic products and services division. Previous to Genzyme, Mike held sales and marketing positions at Repligen and Bristol-Myers. Mike received a Bachelor of Arts from DePauw University.